[Edaily Reporter Shin Ha-yeon ] NeoImmuneTech, Inc.(950220)has hit the daily price limit for two consecutive days following news of a large-scale technology transfer agreement regarding the thymus dysfunction indication for NT-I7.

According to MP Doctor on the 21st, as of 9:13 a.m., NeoImmuneTech, Inc. is trading at 2,850 won, up 29.84% from the previous trading day. Following a 29.88% gain to close at 2,195 won the previous day, the stock is now hitting the daily price limit for the second consecutive trading day.

NeoImmuneTech, Inc. announced on the 19th that it had signed an agreement with U.S.-based Tolerance Bio to transfer exclusive development and commercialization rights for NT-I7 for indications related to thymic hypofunction, including immune reconstitution in people living with HIV. The agreement covers North America, South America, Central America, and Europe.

The total value of the technology transfer is $260 million (approximately 366.9 billion won) plus a 4% equity stake in the counterparty. The upfront payment will be received in the form of a 4% stake in Tolerance Bio’s common stock, and the company will receive milestone payments totaling $260 million based on future clinical development and sales achievements. It will also receive separate tiered royalties based on annual net sales.

Notably, key areas currently under development by NeoImmuneTech, Inc.—such as immuno-oncology—are excluded from this agreement, and the company will retain the related rights. This combination of a major technology transfer achievement and the retention of rights to its existing core pipeline is seen as a factor that has boosted investor sentiment.